[1]林梦璐,谢玉才.血液中有形成分在心房颤动血栓形成中的作用[J].国际心血管病杂志,2022,01:25-27,47.
点击复制
血液中有形成分在心房颤动血栓形成中的作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年01期
- 页码:
- 25-27,47
- 栏目:
- 综述
- 出版日期:
- 2022-02-10
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.01.007
- 文献标识码:
- -
- 摘要:
- 心房颤动（房颤）是较为常见的心律失常，以往研究多关注左心耳局部因素和 血液中无形成分对房颤血栓形成的影响，但越来越多的研究发现，血液中各种有形成分，如血 小板、单核细胞、巨噬细胞、淋巴细胞、红细胞、粒细胞、循环微粒等，对房颤血栓形成也 起到重要的作用。
- Abstract:
- -
参考文献/References
[1] Benjamin EJ, Muntner P, Alonso AA, et al. Heart disease and
stroke statistics—2019 update a report from the American
Heart Association[J]. Circulation, 2019, 139(10):E56-E528.
[2] Wang CC, Lin CL, Gj W, et al. Atrial fibrillation associated
with increased risk of venous thromboembolism. A populationbased
cohort study[J]. Thromb Haemost, 2015, 113(1):185-
192.
[3] Sundb?ll J, Hováth-Puhó E, Adelborg K, et al. Risk of arterial
and venous thromboembolism in patients with atrial fibrillation
or flutter: a nationwide population-based cohort study[J]. Int J
Cardiol, 2017, 241:182-187.
[4] Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation
and future risk of venous thromboembolism: the Troms?
study[J]. J Thromb Haemost, 2015, 13(1):10-16.
[5] Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis
in atrial fibrillation: Virchow's triad revisited[J]. Lancet, 2009,
373(9658):155-166.
[6] Khan AA, Lip GYH. The prothrombotic state in atrial
fibrillation: pathophysiological and management
implications[J]. Cardiovasc Res, 2019, 115(1):31-45.
[7] Pongratz G, Brandt-Pohlmann M, Henneke KH, et al. Platelet
activation in embolic and preembolic status of patients with
nonrheumatic atrial fibrillation[J]. Chest, 1997, 111(4):929-933.
[8] Choudhury A, Chung I, Blann AD, et al. Elevated platelet
microparticle levels in nonvalvular atrial fibrillation:
relationship to p-selectin and antithrombotic therapy[J]. Chest,
2007, 131(3):809-815.
[9] Fu R, Wu S, Wu P, et al. A study of blood soluble P-selectin,
fibrinogen, and von Willebrand factor levels in idiopathic and
lone atrial fibrillation[J]. Europace, 2011, 13(1):31-36.
[10] Makowski M, Smor?g I, Bissinger A, et al. Effect of sinus
rhythm restoration on platelet function in patients with lone
atrial fibrillation[J]. Int J Cardiol, 2014, 172(1):e22-e23.
[11] Wu N, Tong S, Xiang Y, et al. Association of hemostatic
markers with atrial fibrillation: a meta-analysis and metaregression[
J]. PLoS One, 2015, 10(4):e0124716.
[12] Makowski M, Baj Z. Platelet reactivity and mean platelet
volume as risk markers of thrombogenesis in atrial
fibrillation[J]. Int J Cardiol, 2017, 244:204.
[13] Choi SW, Kim BB, Choi DH, et al. Stroke or left atrial
thrombus prediction using antithrombin Ⅲ and mean platelet
volume in patients with nonvalvular atrial fibrillation[J]. Clin
Cardiol, 2017, 40(11):1013-1019.
[14] Martischnig AM, Mehilli J, Pollak J, et al. Impact of
dabigatran versus phenprocoumon on ADP induced platelet
aggregation in patients with atrial fibrillation with or without
concomitant clopidogrel therapy (the Dabi-ADP-1 and Dabi-
ADP-2 trials)[J]. Biomed Res Int, 2015, 2015:798486.
[15] Duzen IV, Oguz E, Cekici Y, et al. Effect of new oral
anticoagulants on platelet indices in non-valvular atrial
fibrillation patients[J]. Herz, 2021, 46(1):76-81.
[16] Voukalis C, Lip GYH, Shantsila E. Effects of antithrombotic
drugs on the prothrombotic state in patients with atrial
fibrillation: the west Birmingham atrial fibrillation project[J].
Thromb Res, 2021, 200:149-155.
[17] Peshkova AD, Le Minh G, Tutwiler V, et al. Activated
monocytes enhance platelet-driven contraction of blood clots
via tissue factor expression[J]. Sci Rep, 2017, 7(1):5149.
[18] Allen N, Barrett TJ, Guo Y, et al. Circulating monocyteplatelet
aggregates are a robust marker of platelet activity in
cardiovascular disease[J]. Atherosclerosis, 2019, 282:11-18.
[19] Lukasik M, Dworacki G, Kufel-Grabowska J, et al.
Upregulation of CD40 ligand and enhanced monocyteplatelet
aggregate formation are associated with worse clinical
outcome after ischaemic stroke[J]. Thromb Haemost, 2012,
107(2):346-355.
[20] Pfluecke C, Tarnowski D, Plichta L, et al. Monocyteplatelet
aggregates and CD11b expression as markers for
thrombogenicity in atrial fibrillation[J]. Clin Res Cardiol,
2016, 105(4):314-322.
[21] He G, Tan W, Wang B, et al. Increased M1 macrophages
infiltration is associated with thrombogenesis in rheumatic
mitral stenosis patients with atrial fibrillation[J]. PLoS One,
2016, 11(3):e0149910.
[22] Liu Y, Shi Q, Ma Y, et al. The role of immune cells in atrial
fibrillation[J]. J Mol Cell Cardiol, 2018, 123:198-208.
[23] Sulzgruber P, Thaler B, Koller L, et al. CD4＋CD28null T
lymphocytes are associated with the development of atrial
fibrillation after elective cardiac surgery[J]. Sci Rep, 2018,
8(1):9624.
[24] Kazem N, Sulzgruber P, Thaler B, et al. CD8＋CD28null T
lymphocytes are associated with the development of atrial
fibrillation after elective cardiac surgery[J]. Thromb Haemost,
2020, 120(8):1182-1187.
[25] ?im?ek B, Altay S, ?zbilgin N, et al. Autoimmune activation
as a determinant of atrial fibrillation among Turks: a
prospective evaluation[J]. Medicine (Baltimore), 2018,
97(31):e11779.
[26] Melduni RM, Cooper LT, Gersh BJ, et al. Association of
autoimmune vasculitis and incident atrial fibrillation: a
population-based case-control study[J]. J Am Heart Assoc,
2020, 9(18):e015977.
[27] Yalcin M, Aparci M, Uz O, et al. Neutrophil-lymphocyte ratio
may predict left atrial thrombus in patients with nonvalvular
atrial fibrillation[J]. Clin Appl Thromb Hemost, 2015,
21(2):166-171.
[28] Kaya MG, Akpek M, Elcik D, et al. Relation of left atrial
spontaneous echocardiographic contrast in patients with mitral
stenosis to inflammatory markers[J]. Am J Cardiol, 2012,
109(6):851-855.
[29] Saliba W, Barnett-Griness O, Elias M, et al. Neutrophil to
lymphocyte ratio and risk of a first episode of stroke in patients
with atrial fibrillation: a cohort study[J]. J Thromb Haemost,
2015, 13(11):1971-1979.
[30] Gungor B, Ozcan KS, Erdinler I, et al. Elevated levels of
RDW is associated with non-valvular atrial fibrillation[J]. J
Thromb Thrombolysis, 2014, 37(4):404-410.
[31] Zhao JP, Liu T, Korantzopoulos P, et al. Red blood cell
distribution width and left atrial thrombus or spontaneous echo
contrast in patients with non-valvular atrial fibrillation[J]. Int J
Cardiol, 2015, 180:63-65.
[32] Kurt M, Tanboga IH, Buyukkaya E, et al. Relation of red cell
distribution width with CHA2DS2-VASc score in patients with
nonvalvular atrial fibrillation[J]. Clin Appl Thromb Hemost,
2014, 20(7):687-692.
[33] Masawa N, Yoshida Y, Yamada T, et al. Diagnosis of cardiac
thrombosis in patients with atrial fibrillation in the absence of
macroscopically visible thrombi[J]. Virchows Arch A Pathol
Anat Histopathol, 1993, 422(1):67-71.
[34] Diao SL, Xu HP, Zhang B, et al. Associations of MMP-2,
BAX, and Bcl-2 mRNA and protein expressions with
development of atrial fibrillation[J]. Med Sci Monit, 2016,
22:1497-1507.
[35] Wang P, Cheng M, Wang P, et al. SNP rs2243828 in MPO
associated with myeloperoxidase level and atrial fibrillation
risk in Chinese Han population[J]. J Cell Mol Med, 2020,
24(17):10263-10266.
[36] Ramacciotti E, Hawley AE, Farris DM, et al. Leukocyte-and
platelet-derived microparticles correlate with thrombus weight
and tissue factor activity in an experimental mouse model of
venous thrombosis[J]. Thromb Haemost, 2009, 101(4):748-
754.
[37] Mallat Z, Hugel B, Ohan J, et al. Shed membrane
microparticles with procoagulant potential in human
atherosclerotic plaques: a role for apoptosis in plaque
thrombogenicity[J]. Circulation, 1999, 99(3):348-353.
[38] Simak J, Gelderman MP, Yu H, et al. Circulating endothelial
microparticles in acute ischemic stroke: a link to severity,
lesion volume and outcome[J]. J Thromb Haemost, 2006,
4(6):1296-1302.
[39] Wang L, Bi Y, Yu M, et al. Phosphatidylserine-exposing blood
cells and microparticles induce procoagulant activity in nonvalvular
atrial fibrillation[J]. Int J Cardiol, 2018, 258:138-143.
[40] Siwaponanan P, Keawvichit R, Udompunturak S, et al. Altered
profile of circulating microparticles in nonvalvular atrial
fibrillation[J]. Clin Cardiol, 2019, 42(4):425-431.
[41] Liles J, Liles J, Wanderling C, et al. Increased level of
thrombotic biomarkers in patients with atrial fibrillation
despite traditional and new anticoagulant therapy[J]. Clin Appl
Thromb Hemost, 2016, 22(8):743-748.
[42] Pourtau L, Sellal JM, Lacroix R, et al. Platelet function and
microparticle levels in atrial fibrillation: changes during the
acute episode[J]. Int J Cardiol, 2017, 243:216-222.
备注/Memo
- 备注/Memo:
- 通信作者：谢玉才， E-mail:drxieyucai@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed0
- 全文下载/Downloads413
- 评论/Comments
